156 related articles for article (PubMed ID: 21108444)
41. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
42. Increased HbF in sickle cell anemia is determined by a factor linked to the beta S gene from one parent.
Milner PF; Leibfarth JD; Ford J; Barton BP; Grenett HE; Garver FA
Blood; 1984 Jan; 63(1):64-72. PubMed ID: 6197115
[TBL] [Abstract][Full Text] [Related]
43. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
44. A method of HbF determination for potential use in underdeveloped countries.
Schumacher SN; Randolph TR
Clin Lab Sci; 2012; 25(4):212-8. PubMed ID: 23330510
[TBL] [Abstract][Full Text] [Related]
45. Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
Allard P; Alhaj N; Lobitz S; Cario H; Jarisch A; Grosse R; Oevermann L; Hakimeh D; Tagliaferri L; Kohne E; Kopp-Schneider A; Kulozik AE; Kunz JB
Haematologica; 2022 Jul; 107(7):1577-1588. PubMed ID: 34706496
[TBL] [Abstract][Full Text] [Related]
46. Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.
Zhang Y; Paikari A; Sumazin P; Ginter Summarell CC; Crosby JR; Boerwinkle E; Weiss MJ; Sheehan VA
Blood; 2018 Jul; 132(3):321-333. PubMed ID: 29884740
[TBL] [Abstract][Full Text] [Related]
47. Pathophysiology and recent therapeutic insights of sickle cell disease.
Shah F; Dwivedi M
Ann Hematol; 2020 May; 99(5):925-935. PubMed ID: 32157419
[TBL] [Abstract][Full Text] [Related]
48. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
49. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
50. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
51. Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion.
Setty BN; Kulkarni S; Dampier CD; Stuart MJ
Blood; 2001 May; 97(9):2568-73. PubMed ID: 11313243
[TBL] [Abstract][Full Text] [Related]
52. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT
Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294
[TBL] [Abstract][Full Text] [Related]
53. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
[TBL] [Abstract][Full Text] [Related]
54. Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.
Mundee Y; Bigelow NC; Davis BH; Porter JB
Clin Lab Haematol; 2001 Jun; 23(3):149-54. PubMed ID: 11553054
[TBL] [Abstract][Full Text] [Related]
55. Fetal hemoglobin and F-cell variance in mobilized CD34
Demirci S; Mora JJH; Yapundich M; Drysdale C; Gamer J; Nassehi T; Bonifacino AC; Krouse AE; Linde NS; Donahue RE; Tisdale JF; Uchida N
Exp Hematol; 2019 Jul; 75():21-25.e1. PubMed ID: 31173819
[TBL] [Abstract][Full Text] [Related]
56. The determinants of irreversibly sickled cells in homozygous sickle cell disease.
Serjeant GR; Serjeant BE; Desai P; Mason KP; Sewell A; England JM
Br J Haematol; 1978 Nov; 40(3):431-8. PubMed ID: 749928
[TBL] [Abstract][Full Text] [Related]
57. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
58. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
59. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
60. Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes.
Dover GJ; Boyer SH; Zinkham WH
J Clin Invest; 1979 Feb; 63(2):173-6. PubMed ID: 429549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
